Targeted Therapies Linked to Survival Benefits for Older Patients With Advanced Renal Cancer

Targeted therapies were associated with “modest survival advantages” in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.
Reuters Health Information